Sun Pharmaceutical Industries Limited has entered into a license agreement with U.S.-based biopharmaceutical company Pharmazz Inc. for the commercialization of the first-in-class innovative drug, Tyvalzi (Sovateltide), in India. The deal terms include undisclosed upfront and milestone payments, as well as royalties to Pharmazz. Sovateltide is indicated for treating cerebral ischemic stroke and has recently been […]
BRILINTA FDA approval : AstraZeneca has bagged approval for BRILINTA (ticagrelor) from the US Food and Drug Administration for its use in reducing the risk of stroke in patients having acute ischemic stroke or high-risk transient ischemic attack (TIA). The FDA approval was driven by the positive results from the THALES phase 3 clinical trial […]
Seneca Biopharma (formerly Neuralstem), a biopharma company engaged in developing treatments for diseases of high unmet medical need, has completed construction on its new cell manufacturing facility in Suzhou, China. The cell manufacturing facility will be used for manufacture NSI-566, the lead stem cell therapy of Seneca Biopharma for clinical trials in China, which includes […]
Oral Contraceptives, commonly known as birth control pills are known to block blood flow to the brain which may result in ischemic strokes. However, Ischemic strokes risk is very small among women who do not have other stroke risk factors. Birth control pills may result in blood clots that block the blood vessel in the […]